AML with FLT3-ITD (without adverse-risk genetic lesions) is classified as intermediate risk [25], but there is limited evidence to support the reclassification of AML with CEBPAbZIP-inf- FLT3-ITD mutations. Here, FLT3 is linked to acute myeloid leukemia.